The cyclosaligenyl (cycloSal) derivatives of the monophosphates of three acyclic or carbocyclic guanosine analogues, for example, acyclovir (ACV), carbovir (CBV) and abacavir (ABC), were investigated for their activity against retrovirus (HIV, Moloney sarcoma virus) and herpes simplex virus (HSV) activity in cell culture. The extent of the antiviral potency of the prodrugs depended on the nature of the nucleoside, the substituent on the cycloSal moiety and the virus investigated. Most notably, and unlike the parent compound ACV, cycloSal-ACV monophosphate (MP) prodrugs retained pronounced activity against ACV-resistant (thymidine kinase-deficient) HSV-1 and also gained anti-HIV activity. While the cycloSal-CBVMP prodrugs did not show enhanced activity compared with the parent compound CBV, the cycloSal-ABCMP prodrugs afforded markedly increased potency against both HSV and HIV. Our data indicate that the cycloSal prodrug approach can be useful to deliver directly the MP derivatives of nucleoside analogues into the intact, virus-infected cells, thus improving and extending the antiviral potency and spectrum of the drugs against retro- and herpesvirus strains.
BalzariniJ (1994) Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharmacy World16: 113–126.
2.
BalzariniJWedgwoodOKruiningJPelemansHHeijtinkRDe ClercqE & McGuiganC (1996) Anti-HIV and anti-HBV activity and resistance profile of 2′,3′,-dideoxy-3′,-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochemical and Biophysical Research Communications225: 363–369.
3.
BalzariniJKarlssonAAquaroSPernoCFCahardDNaesensLDe ClercqE & McGuiganC (1996a) Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proceedings of the National Academy of Sciences, USA93: 7295–7299.
4.
BalzariniJEgberinkHHartmannKCahardDVahlenkampTThormarHDe ClercqE & McGuiganC (1996b) Antiretrovirus specificity and intracellular metabolism of 2′,3′,-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate triester prodrug So324. Molecular Pharmacology50: 1207–1213.
5.
BalzariniJCahardDWedgwoodOSalgadoAVelazquezSYarnoldCJDe ClercqEMcGuiganC & ThormarH (1998) Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology17: 296–302.
6.
BalzariniJNaesensLAquaroSKnispelTPernoCFDe ClercqE & MeierC (1999) Intracellular metabolism of cyclosaligenyl 3′-azido-2′,3′,-dideoxythymidine monophosphate, a prodrug of 3′-azido-2′,3′-dideoxythymidine (zidovudine). Molecular Pharmacology56: 1354–1361.
ChengY-CGaoW-YChenC-HVazquez-PaduaM & StarnesMC (1990) DNA polymerases versus HIV reverse transcriptase in AIDS therapy. Annals of the New York Academy of Sciences616: 217–223.
9.
De ClercqE & MeriganTC (1971) Moloney sarcoma virus-induced tumors in mice: Inhibition or stimulation by (polyrI:polyrC). Proceedings of the Society for Experimental Biology and Medicine137: 590–594.
10.
De ClercqEDescampsJVerhelstGWalkerRTJonesASTorrencePF & ShugarD (1980) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Diseases141: 563–574.
11.
FarquharDNowakBKhanS & PlunkettW (1991) A strategy to introduce therapeutic nucleoside 5′-phosphates into cells. Antiviral Research15: 143.
12.
FarquharDKhanSSirvastavaDN & SaundersPP (1994) Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2′-deoxy-5-fluorouridine 5′-monophosphate (FdUMP): A strategy to introduce nucletoides into cells. Journal of Medicinal Chemistry37: 3920–3909.
13.
LefebvreIPerigaudCPomponAAubertinAMGirardetJLKirnAGosselinG & ImbachJL (1995) Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. Journal of Medicinal Chemistry38: 3941–3950.
14.
MartinJLBrownCEMatthews-DavisN & ReardonJE (1994) Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy38: 2743–2749.
15.
McGuiganCCahardDSheekaHMDe ClercqE & BalzariniJ (1996a) Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. Journal of Medicinal Chemistry39: 1748–1753.
16.
McGuiganCWedgwoodOMDe ClercqE & BalzariniJ (1996b) Phosphoramidate derivatives of 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) have markedly improved anti-HIV potency and selectivity. Bioorganic & Medicinal Chemistry Letters6: 2359–2362.
17.
MeierC (1998) Pro nucleotides recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synletters: 233–242.
18.
MeierCHabelLHaller-MeierFLompAHerderichMKlockingRMeerbachA & WutzlerP (1998a) Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues. Antiviral Chemistry & Chemotherapy9: 389–402.
19.
MeierCLoreyMDe ClercqE & BalzariniJ (1998b) CycloSal-2′,3′,-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP) — Synthesis and antiviral evaluation of a new d4TMP delivery system. Journal of Medicinal Chemistry41: 1417–1427.
20.
MeierCKnispelTDe ClercqE & BalzariniJ (1999a) CycloSal pronucleotides of 2′,3′,-dideoxyadenosine and 2′,3′,-dideoxy-2′,3′- didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. Journal of Medicinal Chemistry42: 1604–1614.
21.
MeierCKnispelTMarquezVESiddiquiMADe ClercqE & BalzariniJ (1999b) CycloSal-pronucleotides of 2′,-fluoro-ara- and 2′,-fluoro-ribo-2′,3′,-dideoxyadenosine as a strategy to bypass a metabolic blockade. Journal of Medicinal Chemistry42: 1615–1624.
22.
MeierCLompAMeerbachA & WutzlerP (2001) cycloSaligenyl-5-[(E)-2-bromovinyl]-2′-deoxyuridine monophosphate (cycloSal-BVDUMP) pronucleotides active against Epstein-Barr-virus. ChemBioChem2: 283–285.
23.
PerigaudCGosselinGLefebvreIGirardetJLBenzariaSBarberI & ImbachJL (1993) Rational design for cytosolic delivery of nucleoside monophosphates: “SATE” and “DTE” as enzyme-labile transient phosphate protecting groups. Bioorganic & Medicinal Chemistry Letters3: 2521–2526.
24.
SiddiquiAQBallatoreCMcGuiganCDe ClercqE & BalzariniJ (1999) The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship. Journal of Medicinal Chemistry42: 393–399.
25.
ValetteGPomponAGirardetJLCappellacciLFranchettiPGrifantiniMLa CollaPLoiAGPerigaudCGosselinG & ImbachJL (1996) Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. Journal of Medicinal Chemistry39: 1981–1990.
26.
WagnerCRIyerVV & McInteeEJ (2000) Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Medicinal Research Reviews20: 417–451.
